<DOC>
	<DOC>NCT01086384</DOC>
	<brief_summary>This study will establish the safety as well as demonstrate benefit of the addition of a LABA to an ICS by utilizing an endpoint (time to first severe asthma exacerbation) that informs on both safety and efficacy.</brief_summary>
	<brief_title>Asthma Exacerbation Study</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Clinical diagnosis of asthma Reversibility FEV1 of twelve percent or greater and two hundred milliliters and greater approximately ten to forty minutes following two to four inhalations of albuterol FEV1 of fifty to ninety percent of predicted Currently using inhaled corticosteroid therapy History of one or more asthma exacerbations requiring treatment with oral/systemic corticosteroids or emergency department visit or inpatient hospitalization in previous year History of life threatening asthma in previous 5 years (requiring intubation, and/or associated with hypercapnia, hypoxic seizure or respiratory arrest Respiratory infection or oral candidiasis Uncontrolled disease or clinical abnormality Allergies Taking another investigational medication or prohibited medication</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>